The company won approval from Clalit Health Services to deploy its INSPIRA ART100 system across a network of around 4.9 million members.
Shares of Inspira Technologies OXY (IINN) popped over 28% in pre-market trading on Monday after Israel’s largest health services provider approved the procurement of its FDA-cleared ART100 platform.
The company secured approval from Clalit Health Services’ Medical Equipment Committee, allowing its INSPIRA ART100 system to be immediately procured and deployed across a healthcare network serving roughly 4.9 million members.
With this step, ART100 moves from regulatory clearance to active commercial availability, marking a significant growth opportunity for Inspira and strong clinical validation.
The company’s FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and for (Extracorporeal Membrane Oxygenation) ECMO procedures outside the U.S.
Read updates to this developing story on Stocktwits.<
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
-
BCCI Releases Central Contract List: Virat Kohli & Rohit Sharma Demoted, Only Three Players In Grade A
-
'National Interest Drives Our Decision': Foreign Secretary Vikram Misri On Russian Oil Imports
-
ICC Rejects Pakistan Cricket Board's Demands To End India Vs Pakistan ICC T20 WC26 Match Boycott: Reports
-
Ranji Trophy 2025/26: Jammu & Kashmir Enter Maiden Semifinals After Auqib Nabi's 12-Wicket Haul
-
Shreyas Iyer’s Punjab Kings kicks off IPL 2026 preparations with training camp at…
